Joanna Applequist
Patents and Intellectual Property – Strategic Aspects
By Joanna Applequist, Mikael Henriksson | Posted on February 6, 2023
As part of Redeye’s ProView series, Jessica Martinsson, COO of Sprint Bioscience joins European patent attorneys Joanna Applequist and Mikael Henriksson, as well as Redeye’s equity analyst Ethel Luvall to discuss patents, intellectual property and dive deep into the legal and strategic aspects of different businesses. ...
Determining the Value of Patents during an Investment or Sale
By Joanna Applequist, Mikael Henriksson | Posted on October 1, 2021
Joanna Applequist and Mikael Henriksson speak on IP matters that companies should consider preparing for during an investment or sale during this seminar hosted by Stockholm Science City. Joanna and Mikael were joined by David Bejker from Affibody AB and Jonas Jendi from Industrifonden. This webinar is in Swedish.
Tags: investment, patents, sale, strategy
Nobel prize awarded to Crispr-patent tussle party Charpentier and Doudna
By Joanna Applequist | Posted on October 7, 2020
The Nobel committee has announced that this year’s prize in Chemistry is awarded to Doudna and Charpentier for their groundbreaking research leading to the development of the Crispr-Cas 9 technology, often referred to as the gene scissors. The Crispr-Cas 9 technology was first published as a scientific paper in 2012 by Doudna and Charpentier. This...
Tags: Broad Institute, Crispr-Cas 9, Nobel, Patent, UC Berkley
Patenting Antibody and Cell Therapies – What to Do and What Not to Do
By Joanna Applequist, Louise Jonshammar, Niklas Mattsson | Posted on September 28, 2020
Antibody drugs and cell therapies are at the heart of new biotechnology science. Not only do they show great promise when it comes to curing disease and helping patients, but also in creating value and growth. Biotech companies need to protect their scientific results and the corresponding investments with strong and durable patents. This is...
Tags: antibodies, Biotechnology, cell therapies, EPO, Litigation, patents
The Crispr-Cas9 patent tussle continues: The case of UC Berkeley at the EPO
By Joanna Applequist | Posted on November 15, 2019
In Europe, we don’t do things the way the Americans do… Oral proceedings in the opposition against UC Berkeley’s (UC’s) main European patent EP2800811 are scheduled for all of three (!) days in February of 2020 at the European Patent Office (EPO). The opposition division’s (OD’s) preliminary and non-binding opinion, provided on the 30th of...
Recent contributors
Partner, European Patent Attorney
Senior Associate, Attorney at Law
Partner, Attorney at Law, Group Vice President
Partner, Attorney at Law, Business Area Manager
Senior Counsel, European Patent Attorney
